Current Drug Targets
Volume 21, 16 Issues, 2020
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
  |
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
Current Drug Targets, Volume 17 - Number 6
Editorial Open Access
Editorial Open Access
CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses
, 17(6): 619 - 629Marion H. Brown
DOI: 10.2174/1389450116666150825120536
CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses
, 17(6): 630 - 639Rita F. Santos, Liliana Oliveira and Alexandre M. Carmo
DOI: 10.2174/1389450116666150531152439
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses
Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
, 17(6): 640 - 650Adelaida Sarukhan, Mario Martinez-Florensa, Cristina Escoda-Ferran, Esther Carrasco, Esther Carreras and Francisco Lozano
DOI: 10.2174/1389450116666150316224308
Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
, 17(6): 651 - 665David M. Kofler, Aron Farkas, Michael von Bergwelt-Baildon and David A. Hafler
DOI: 10.2174/1389450117666160201105934
The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
, 17(6): 666 - 677Patricia Hernández, Ernesto Moreno, Lazaro E. Aira and Pedro C. Rodríguez
DOI: 10.2174/1389450117666160201114308
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy
, 17(6): 678 - 692Sundararaj Stanley Jeremiah, Kenji Ohba and Naoki Yamamoto
DOI: 10.2174/138945011706160324125824
Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy
Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
, 17(6): 693 - 701Maria J. Alvarez-Cubero, Fernando Vázquez-Alonso, Ignacio Puche-Sanz, F. Gabriel Ortega, M. Martin-Prieto, José L. Garcia-Puche, Manrique Pascual-Geler, José A. Lorente, José M. Cozar-Olmo and Maria J. Serrano
DOI: 10.2174/1389450116666150309121346
Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria
, 17(6): 702 - 719Yinhu Wang, Henrietta Venter and Shutao Ma
DOI: 10.2174/1389450116666151001103948
Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria
Advances in Hyaluronic Acid-Based Drug Delivery Systems
, 17(6): 720 - 730Yan Jiao, Xin Pang and Guangxi Zhai
DOI: 10.2174/1389450116666150531155200
Advances in Hyaluronic Acid-Based Drug Delivery Systems
New Antimicrobial Approaches: Reuse of Old Drugs
, 17(6): 731 - 738Dianella Savoia
DOI: 10.2174/1389450116666150806124110
New Antimicrobial Approaches: Reuse of Old Drugs
Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
, 17(6): 739 - 745David M. Straughan, Sa d C. Azoury and Vivek Shukla
DOI: 10.2174/1573399811666150615144336
Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Editor-in-Chief
Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
(USA)
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Drug Targets Journal was launched in 2000. Dr. Francis J. Castellino serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.63
Advertisement
Webmaster Contact: info@benthamscience.net